AHR and psoriasis: With multiDE, the estimated ud for the three conditions (vehicle control, AhR agonist, and AhR antagonist) were 1, −4.20, and 3.20, respectively, which coincided with the fact that AhR-activating ligands reduced inflammation in the lesion of psoriasis patients and AhR antagonists upregulated inflammation.